{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-311276","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.454909+00:00","generated_at":"2026-05-16T14:00:51.335800+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcellx: anito-cel achieves 96% ORR, 74% CR/sCR in pivotal RRMM study","bullets":["96% ORR (112/117) and 74% CR/sCR (86/117); 95% MRD negativity (91/96) at 10^-5 sensitivity.","12-month PFS 82.1%, OS 94.0%; 24-month PFS 61.7%, OS 83.0% in 4L+ triple/penta-refractory patients.","No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) observed; all patients dosed >12 months.","Company reiterates planned 2026 commercial launch; building commercial and medical affairs organization.","Data presented at ASH; BLA submission underway with Oct 2025 data cutoff."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-311276","json":"https://secwatch.observer/filing/0001193125-25-311276.json","markdown":"https://secwatch.observer/filing/0001193125-25-311276.md","text":"https://secwatch.observer/filing/0001193125-25-311276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525311276/0001193125-25-311276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525311276/d89813d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:00:51.335800+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}